MacroGenics (MGNX) Corporate presentation summary

Strategic focus and financial position

• Focus on developing next-generation antibody-based therapeutics for cancer using proprietary DART and TRIDENT platforms, with a broad clinical pipeline and three FDA-approved therapies out-licensed or sold to partners.

• Maintains $154.2M in cash as of March 31, 2026, with a projected cash runway through 2028, supported by $352M in non-dilutive capital generated in 2025-26.

• Eligible for significant milestone and royalty payments from partnerships with Gilead, Sanofi, Incyte, and TerSera, totaling over $2.4B in potential future payments.

• Recent financial moves include the sale of manufacturing operations and ZYNYZ royalty rights, and a $24.5M milestone from Sanofi for TZIELD approval.

Pipeline highlights and clinical development

• MGC026, a B7-H3 ADC, shows encouraging safety and anti-tumor activity across multiple cancers, with SCCHN emerging as a lead indication and full dose escalation results to be presented at ESMO 2026.

• MGC028, an ADAM9 ADC, is in Phase 1 dose escalation with initial results expected in 2H2026, targeting cancers with high ADAM9 expression such as NSCLC and GI cancers.

• MGC030 targets an undisclosed antigen in solid tumors, with IND submission planned for 3Q2026 and favorable preclinical safety and efficacy data.

• Lorigerlimab, a dual checkpoint DART molecule (PD-1 × CTLA-4), is advancing in clear cell gynecologic cancer (CCGC) with a new cohort enrolling at a lower dose to improve safety.

• MGD024, a CD123 × CD3 DART molecule for hematologic malignancies, is in Phase 1 and subject to an exclusive option with Gilead.

Market opportunities and unmet needs

• Significant unmet need exists in SCCHN, with poor response rates to current therapies and no preferred regimens in later lines, positioning MGC026 as a potential backbone therapy.

• CCGC patients face limited treatment options and poor outcomes, supporting the development of lorigerlimab in this population.

• MGC028 and MGC030 address cancers with high ADAM9 or novel antigen expression, expanding the pipeline's reach into multiple solid tumor indications.